Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,382 across all filing types
Latest filing 2014-09-01 Regulatory Filings
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated September 1, 2014, announcing that regulatory filings (sNDA) for the drug Somatuline® have been accepted by the US FDA (with priority review) and European authorities for GEP-NET treatment. It details the expected decision timelines (Q1 2015 and Q2 2015) and references supporting clinical trial data (CLARINET® Phase III study). This content is a corporate announcement regarding regulatory progress and clinical data dissemination, rather than a full financial report (10-K, IR), a formal audit report (AR), or a general earnings release (ER). It fits best under the category of general regulatory/corporate news that doesn't fit other specific categories, making 'Regulatory Filings' (RNS) the most appropriate fallback, although it is highly specific to regulatory progress. Given the focus on regulatory acceptance and future decisions, it is a significant corporate announcement. Since it is not a formal financial statement, a management discussion, or a specific shareholder communication like a proxy, RNS (Regulatory Filings/General Announcement) is the best fit among the provided options for this type of press release detailing regulatory milestones.
2014-09-01 English
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half (S1) of 2014 for the Ipsen group. It contains detailed financial statements, including consolidated results, income statements, and a thorough management analysis of business trends, sales performance by region, and operational costs. It is not a mere announcement or a short summary, but a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2014
2014-08-29 French
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Earnings Release Classification · 99% confidence The document explicitly states it contains the '2014 half-year results' and presents consolidated financial statements, including an 'Extract of consolidated results' table comparing H1 2014 to H1 2013, and discusses performance metrics like sales, Core Operating Income, and EPS for the first half of the year. This content structure and focus on a period shorter than a full year (half-year) strongly indicate an Interim/Quarterly Report. The document is comprehensive, not just a brief release of highlights, which rules out 'ER'. It is not the full annual report (10-K). Therefore, the classification is Interim / Quarterly Report (IR). H1 2014
2014-08-29 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It presents a table showing the total number of shares and voting rights as of a specific date (July 31, 2014). This content directly relates to the structure of the company's capital and voting rights, which aligns best with the 'Share Issue/Capital Change' (SHA) category, as it is a mandatory disclosure regarding the capital structure, or potentially a general regulatory filing (RNS). However, since it details the total number of shares and voting rights, SHA is the most specific fit among the provided options, as it concerns the capital base. Given the nature of mandatory periodic disclosure on share capital, SHA is selected over the general RNS.
2014-08-06 French
Information relating to the total number of voting rights and shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is titled 'Monthly information regarding the total number of voting rights and total number of shares of the Company' and explicitly references Article 223-16 of the AMF General Regulations. It provides a table detailing the total number of shares and voting rights as of a specific date (July 31, 2014). This content directly relates to the disclosure of voting rights and share capital structure, which is a specific regulatory disclosure. Among the provided codes, none perfectly match a 'Monthly Voting Rights Disclosure'. However, the content is a specific regulatory announcement concerning share structure and voting rights, which is distinct from a general earnings release (ER), interim report (IR), or a director's dealing (DIRS). Since it is a specific regulatory disclosure that doesn't fit the primary categories like 10-K, ER, or IR, and it is not a proxy solicitation (PSI) or dividend notice (DIV), the closest fit among the specific options is difficult. Given the nature of the data (voting rights and share count), it is a fundamental piece of corporate information. If we must choose from the list, it is a specific regulatory filing. Since there is no 'Voting Rights Disclosure' code, I must evaluate the closest fit. It is not a Director's Dealing (DIRS), nor a Major Shareholding Notification (MRQ) which deals with ownership thresholds. It is a mandatory disclosure about the capital structure's voting power. Given the options, and recognizing this is a specific regulatory disclosure, I will check if any code covers general regulatory updates. 'RNS' is the fallback for miscellaneous regulatory filings. However, the content is highly specific to share capital and voting rights. Since the document is short and provides definitive data, it is not an announcement *about* a report (RPA). If the system expects a classification for this specific type of disclosure, and none is provided, 'RNS' (Regulatory Filings) is the safest fallback for a specific, non-standard regulatory notice. Upon re-reviewing the definitions, none fit perfectly. I will classify this as a specific regulatory filing that doesn't fit the main categories, leaning towards RNS as the general regulatory catch-all, although it is highly specific data.
2014-08-06 English
Share buybacks / Liquidity contracts Information related to liquidity contracts
Capital/Financing Update Classification · 99% confidence The document text explicitly discusses a 'Half-year IPSEN liquidity contract statement' dated June 30, 2014, comparing it to a previous statement from December 31, 2013. This content relates to the management of company shares held under a liquidity agreement, which is a specific type of financial/capital management activity. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR) which focuses on comprehensive financial statements. It is most closely related to capital structure changes or specific financial arrangements. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate fit as it deals with the mechanics of share liquidity management, which is a financing/capital activity. It is too specific for the general 'Regulatory Filings' (RNS) fallback.
2014-08-01 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.